Michael Grasso, MD
Urology · New York, NYNPI 1437184280
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $269,358 of the $284,325 with a category attached, or 94.7%. KARL Storz Endovision, Inc. accounts for 95.0% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $180,775 and has fallen 100.0% since, to $3 in 2025. Among urology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 10 payments — averaging $28,433 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- KARL Storz Endovision, Inc.$270K
- KARL Storz Endoscopy-america$14K
- Koelis Inc.$192
- Olympus America Inc.$99
- Travere Therapeutics, Inc.$3
What the payments were for
- Royalty or licence$269,35895%
- Travel & lodging$13,8835%
- Food & beverage$2920%
- Education$30%
- Charitable contribution$7900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| KARL Storz Endovision, Inc. | 4 | $270,148 |
| KARL Storz Endoscopy-america | 3 | $13,883 |
| Koelis Inc. | 1 | $192 |
| Olympus America Inc. | 1 | $99 |
| Travere Therapeutics, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CMOS VIDEO URETEROSCOPE, 8.5 FR. X 675MM$275,387
- URETERO-RENO-FIBERSCOPE FLEX-X$7,854
- LIGHT CABLE$790
- TRINITY$192
How this compares
$284,325 in reported general payments places this provider in the 95th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Citrate ErPotassium Citrate | 79 | $16,295 |
| MyrbetriqMirabegron | 18 | $9,276 |
| Tamsulosin Hcl | 332 | $5,476 |
| Dutasteride | 71 | $2,620 |
| Silodosin | 31 | $2,182 |
| Bicalutamide | 76 | $1,960 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 12 | $1,204 |
| Ciprofloxacin Hcl | 157 | $1,141 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 39 | $962 |
| Tadalafil | 13 | $783 |
| Finasteride | 29 | $435 |
| Methenamine Hippurate | 11 | $410 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 15 | $398 |
| CefuroximeCefuroxime Axetil | 17 | $280 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 32 | $276 |
Paid to pharmacies, not to this prescriber.
Other urology in New York
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Kyrollis AttallaNew York$381K
- Benjamin BruckerNew York$364K
- Ketan BadaniNew York$285K
- Mantu GuptaNew York$229K
- Robin SmithNew York$215K
- Jean-Francois EidNew York$146K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.